The Role of Immune Checkpoint Blockade in Uveal Melanoma.

Publication date: Jan 29, 2020

Uveal melanoma (UM) represents the most common intraocular malignancy in adults and accounts for about 5% of all melanomas. Primary disease can be effectively controlled by several local therapy options, but UM has a high potential for metastatic spread, especially to the liver. Despite its clinical and genetic heterogeneity, therapy of metastatic UM has largely been adopted from cutaneous melanoma (CM) with discouraging results until now. The introduction of antibodies targeting CTLA-4 and PD-1 for immune checkpoint blockade (ICB) has revolutionized the field of cancer therapy and has achieved pioneering results in metastatic CM. Thus, expectations were high that patients with metastatic UM would also benefit from these new therapy options. This review provides a comprehensive and up-to-date overview on the role of ICB in UM. We give a summary of UM biology, its clinical features, and how it differs from CM. The results of several studies that have been investigating ICB in metastatic UM are presented. We discuss possible reasons for the lack of efficacy of ICB in UM compared to CM, highlight the pitfalls of ICB in this cancer entity, and explain why other immune-modulating therapies could still be an option for future UM therapies.

Wessely, A., Steeb, T., Erdmann, M., Heinzerling, L., Vera, J., Schlaak, M., Berking, C., and Heppt, M.V. The Role of Immune Checkpoint Blockade in Uveal Melanoma. 25788. 2020 Int J Mol Sci (21):3.

Concepts Keywords
Antibodies Medicine
CM Clinical medicine
Genetic Heterogeneity Organ systems
Immune Checkpoint Blockade Immune system
Liver Bristol-Myers Squibb
Malignancy Antineoplastic drugs
Melanoma Breakthrough therapy
Melanomas Checkpoint inhibitor
Metastatic Ipilimumab
Sci Uveal melanoma
Uveal Melanoma Nivolumab


Type Source Name
disease MESH Uveal Melanoma
disease MESH malignancy
disease MESH melanomas
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab
pathway KEGG Melanoma
drug DRUGBANK Pembrolizumab
disease MESH death


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *